MaxCyte, Inc. (MXCT): Capital Expenditures

Annual figures by period end, from SEC filings.

$1.77M
Year ended 2025-12-31
$665.0K
Trailing 12 months to 2026-06-30
-54.3%
3-year compound annual growth
-3.1%
5-year compound annual growth
$18.48M2019-12-31: $1.27M2020-12-31: $2.07M2021-12-31: $3.83M2022-12-31: $18.48M2023-12-31: $3.70M2024-12-31: $1.65M2025-12-31: $1.77M$1.77M
2019-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$1.77M+7.1%2026-03-25, From 2025-01-01
2024-12-31$1.65M-55.4%2026-03-25, From 2024-01-01
2023-12-31$3.70M-80.0%2025-03-11, From 2023-01-01
2022-12-31$18.48M+381.9%2024-03-12, From 2022-01-01
2021-12-31$3.83M+85.0%2023-03-15, From 2021-01-01
2020-12-31$2.07M+63.0%2022-03-22, From 2020-01-01
2019-12-31$1.27Mn/a2022-03-22, From 2019-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
MaxCyte, Inc. (MXCT)2025-12-31$1.77M+7.1%
OmniAb, Inc. (OABI)2025-12-31$565.0K-69.9%
Foxo Technologies Inc. (FOXO)2025-12-31$62.0Kn/a
NRC Health (NRC)2025-12-31$10.71M-30.7%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$60.6K-23.4%
Absci Corp (ABSI)2025-12-31$1.11M+174.0%
iSpecimen Inc. (ISPC)2025-12-31$454-98.6%
OneMedNet Corp (ONMD)2025-12-31$13.0K-74.5%
Medpace Holdings, Inc. (MEDP)2025-12-31$31.36M-14.2%

Compare MXCT, OABI, FOXO, NRC side by side · Screen every company in Services-Commercial Physical & Biological Research ↗